Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RadioTherapeutics' RF 2000

This article was originally published in The Gray Sheet

Executive Summary

Radiofrequency ablation system is cleared by FDA for treatment of nonresectable liver lesions April 7 through the agency's real-time 510(k) review process. The system initially was approved in 1997 for the general indication of soft tissue necrosis. FDA had cited the company in a May 14, 1998 warning letter for stating in a press release that clinical studies of the product demonstrated "its potential to address the significant need for an alternative or complementary treatment for liver tumors that cannot be removed surgically." Boston Scientific distributes the system in the U.S. for radiological applications. RadioTherapeutics will promote the new indication. The device is targeted at the 90% of the roughly 135,000 patients diagnosed with primary or metastatic liver tumors in the U.S. annually who are not candidates for surgery. The company estimates the worldwide patient population at 2 mil., due in large part to the prevalence of hepatitis C infection in Asia

You may also be interested in...

Zur Rose Calls For Swiss Online Liberalization To Manage Coronavirus OTC Demand

Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts